CML groups (new diagnosed and failed treatment) showed significantly higher methylation levels in the promoter and intron‐1 regions of PTPRG compared to the healthy group. The gene discussed is PTPRG; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.